Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

China's National Medical Products Administration (NMPA) released the draft Regulations on the Administration of Radiopharmaceuticals and opened a public comment period through October 20. The draft establishes a dedicated regulatory…

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein

CompanyDrug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

CompanyDrug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

CompanyDrug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

CompanyDrug

Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023

CompanyDrug

RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors

CompanyDrug

Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors

Company

Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022

Show More